Objective:To develop a new, simple and reproducible method for the quality control of Banxia Xiexin Decoction gastric retention tablets. MethodsTLC was performed for qualitative identification of Scutellaria baicalensisand and Rhizoma Coptidis. HPLC was used for the quantitative analysis of drug release in vitro and determination of baicalin and berberine hydrochloride. Baicalin was quantified on a Diamonsil C,18, column using a mixture of methanol-water-phosphoric (47:53:0.2, v/v/v) as the mobile phase with UV detection at 280 nm, and berberine hydrochloride was quantified using acetonitrile-0.05 mol/L potassium dihydrogen phosphate (50:50, v/v) as the mobile phase with UV detection at 345 nm.  Results:Calibration curves were linear in the concentration range of 4~20 μg/mL of baicalin (Y = 40763X-54322, R,2,=0.9991) and of 5~25 μg/mL of berberine hydrochloride (Y = 62471X-16359, R,2,=0.9997), respectively. The results of methodology study were in line with the requirements. The content of baicalin and berberine hydrochloride was validated to be 19.95±0.72mg / tablet and 13.02±1.05 mg / tablet by determining six batches of Banxia Xiexin Dectotion gastric retention tablets. The release time was confirmed to be 2h, 6h and 10h. After 10h, the release rate was greater than 90%.  Conclusion:A sensitive, reliable, easy and reproducible method was established for qualitative and quantitative analysis of Banxia Xiexin Decoction gastric retention tablets, with the sampling point in accordance with Pharmacopoeia. The method is suitable for the quality control of Banxia Xiexin Decoction gastric retention tablets.